Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-containing induction and maintenance versus standard therapy in newly diagnosed multiple myeloma
NL-OMON29206Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Apr 2005
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Apr 2005; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON29206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29206.